Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates superior glycemic control and weight loss compared to semaglutide and insulin degludec in patients with Type 2 Diabetes.
If you have Type 2 Diabetes and struggle with blood sugar control and weight loss despite other medications, ask your doctor about tirzepatide (Mounjaro). This weekly injection targets two hormones (GIP and GLP-1) and has been shown to be more effective than semaglutide and insulin degludec in lowering blood sugar and reducing weight.
Compared current medications, tirzepatide has a significantly higher rate of therapeutic success... Semaglutide and insulin degludec are inferior to it... When compared to placebo, tirzepatide was found to slow glucose excursions during meal tolerance testing. Thus, tirzepatide was discovered to be effective in the treatment of T2D.
Why this rating
Based on phase 3 clinical trials comparing tirzepatide to other agents.
Source
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Rekha Krishnan et al. · International Journal of Health Sciences and Research · 2023
DOI 10.52403/ijhsr.20230320
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes, with specific agents like liraglutide and semaglutide demonstrating superior efficacy.Strong
- SGLT-2 inhibitors (SGLT-2is) reduce major adverse cardiovascular events and renal outcomes in patients with Type 2 Diabetes, with specific agents like empagliflozin and canagliflozin showing significant benefits.Strong
- Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring systems improve glycemic control and reduce hypoglycemia risk in patients with Type 2 Diabetes, particularly those on insulin therapy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →